## Janet Sultana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2213610/publications.pdf

Version: 2024-02-01

87888 123424 4,407 119 38 61 citations h-index g-index papers 125 125 125 6084 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Assessing intravitreal anti-VEGF drug safety using real-world data: methodological challenges in observational research. Expert Opinion on Drug Safety, 2022, 21, 205-214.	2.4	4
2	Drug-induced Urinary Retention: An Analysis of a National Spontaneous Adverse Drug Reaction Reporting Database. European Urology Focus, 2022, 8, 1424-1432.	3.1	4
3	From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding. Clinical Pharmacology and Therapeutics, 2022, 111, 321-331.	4.7	30
4	Overview of the <scp>European postâ€authorisation study</scp> register postâ€authorization studies performed in Europe from September 2010 to December 2018. Pharmacoepidemiology and Drug Safety, 2022, 31, 689-705.	1.9	9
5	COVID-19 mRNA vaccine safety, immunogenicity, and effectiveness in a hospital setting: confronting the challenge. Internal and Emergency Medicine, 2022, 17, 325-327.	2.0	3
6	Assessment of intravitreal anti-VEGF drugs and dexamethasone for retinal diseases in real world setting: A multi-centre prospective study from Southern Italy. European Journal of Ophthalmology, 2022, , 112067212110734.	1.3	0
7	Orphan Drug Prices and Epidemiology of Rare Diseases: A Cross-Sectional Study in Italy in the Years 2014 $\hat{a}$ €"2019. Frontiers in Medicine, 2022, 9, 820757.	2.6	5
8	Italian guidelines on management of persons with multimorbidity and polypharmacy. Aging Clinical and Experimental Research, 2022, 34, 989-996.	2.9	22
9	Efficacy of Systemic Biologic Drugs in Pediatric Psoriasis: Evidence From Five Selected Randomized Clinical Trials. Frontiers in Pharmacology, 2022, 13, 847308.	3.5	5
10	COVID-19 Patient Management in Outpatient Setting: A Population-Based Study from Southern Italy. Journal of Clinical Medicine, 2022, 11, 51.	2.4	8
11	Cardiovascular risk in patients receiving ranibizumab for exudative age-related macular degeneration: a nationwide self-controlled case-series study. British Journal of Ophthalmology, 2021, 105, 543-548.	3.9	6
12	Direct healthcare costs of chronic kidney disease management in Italy: What costâ€savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesisâ€stimulating agents?. Pharmacoepidemiology and Drug Safety, 2021, 30, 65-77.	1.9	3
13	Advocating a person-centered care approach to drug safety. Expert Opinion on Drug Safety, 2021, 20, 255-258.	2.4	3
14	Psoriasis and psoriasiform reactions secondary to immune checkpoint inhibitors. Dermatologic Therapy, 2021, 34, e14830.	1.7	18
15	Drug safety in thalassemia: lessons from the present and directions for the future. Expert Opinion on Drug Safety, 2021, 20, 937-947.	2.4	2
16	Kidney Disease in Diabetic Patients: From Pathophysiology to Pharmacological Aspects with a Focus on Therapeutic Inertia. International Journal of Molecular Sciences, 2021, 22, 4824.	4.1	35
17	Safety and potential interaction of immunosuppressive drugs for the treatment of inflammatory bowel disease in elderly patients. Minerva Gastroenterology, 2021, , .	0.5	1
18	Incidence of Skin Cancer in Patients With Chronic Inflammatory Cutaneous Diseases on Targeted Therapies: A Systematic Review and Meta-Analysis of Observational Studies. Frontiers in Oncology, 2021, 11, 687432.	2.8	14

#	Article	IF	Citations
19	Association of Influenza Vaccination and Prognosis in Patients Testing Positive to SARS-CoV-2 Swab Test: A Large-Scale Italian Multi-Database Cohort Study. Vaccines, 2021, 9, 716.	4.4	12
20	Are Patients with Psoriasis and Psoriatic Arthritis Undertreated? A Population-Based Study from Southern Italy. Journal of Clinical Medicine, 2021, 10, 3431.	2.4	14
21	Global epidemiology of acromegaly: a systematic review and meta-analysis. European Journal of Endocrinology, 2021, 185, 251-263.	3.7	33
22	Anti-hypertensive drugs deprescribing: an updated systematic review of clinical trials. BMC Family Practice, 2021, 22, 208.	2.9	7
23	Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project. BioDrugs, 2021, 35, 749-764.	4.6	16
24	Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update. BioDrugs, 2021, 35, 673-692.	4.6	19
25	COVID-19 Vaccination in Pregnancy, Paediatrics, Immunocompromised Patients, and Persons with History of Allergy or Prior SARS-CoV-2 Infection: Overview of Current Recommendations and Pre- and Post-Marketing Evidence for Vaccine Efficacy and Safety. Drug Safety, 2021, 44, 1247-1269.	3.2	85
26	Healthcare Database Networks for Drug Regulatory Policies: International Workshop on the Canadian, US and Spanish Experience and Future Steps for Italy. Drug Safety, 2020, 43, 1-5.	3.2	10
27	Potential effects of vaccinations on the prevention of COVID-19: rationale, clinical evidence, risks, and public health considerations. Expert Review of Vaccines, 2020, 19, 919-936.	4.4	72
28	Real World Use of Antidiabetic Drugs in the Years 2011–2017: A Population-Based Study from Southern Italy. International Journal of Environmental Research and Public Health, 2020, 17, 9514.	2.6	5
29	Gender differences in COPD management in a Sicilian general practice setting: a cohort study evaluating the impact of educational interventions. ERJ Open Research, 2020, 6, 00279-2020.	2.6	2
30	Challenges for Drug Repurposing in the COVID-19 Pandemic Era. Frontiers in Pharmacology, 2020, 11, 588654.	3.5	99
31	Safety profiles of biologic agents for inflammatory bowel diseases: a prospective pharmacovigilance study in Southern Italy. Current Medical Research and Opinion, 2020, 36, 1457-1463.	1.9	40
32	Global epidemiology of Duchenne muscular dystrophy: an updated systematic review and meta-analysis. Orphanet Journal of Rare Diseases, 2020, 15, 141.	2.7	202
33	Association Between Intravitreal Aflibercept and Serious Non-ocular Haemorrhage Compared with Intravitreal Ranibizumab: A Multicentre Observational Cohort Study. Drug Safety, 2020, 43, 943-952.	3.2	3
34	The potential role of big data in the detection of adverse drug reactions. Expert Review of Clinical Pharmacology, 2020, 13, 201-204.	3.1	5
35	How Have Intravitreal Anti-VEGF and Dexamethasone Implant Been Used in Italy? A Multiregional, Population-Based Study in the Years 2010–2016. BioMed Research International, 2020, 2020, 1-9.	1.9	4
36	Intravitreal Anti-VEGF Drugs and Signals of Dementia and Parkinson-Like Events: Analysis of the VigiBase Database of Spontaneous Reports. Frontiers in Pharmacology, 2020, 11, 315.	3.5	9

#	Article	IF	Citations
37	The International Society for Pharmacoepidemiology's Comments on the Core Recommendations in the Summary of the Heads of Medicines Agencies (HMA) ―EMA Joint Big Data Task Force. Pharmacoepidemiology and Drug Safety, 2019, 28, 1640-1641.	1.9	2
38	Analgesic drug use in elderly persons: A population-based study in Southern Italy. PLoS ONE, 2019, 14, e0222836.	2.5	13
39	Measuring the Effectiveness of Safety Warnings on the Risk of Stroke in Older Antipsychotic Users: A Nationwide Cohort Study in Two Large Electronic Medical Records Databases in the United Kingdom and Italy. Drug Safety, 2019, 42, 1471-1485.	3.2	9
40	Role of healthcare databases and registries for surveillance of orphan drugs in the real-world setting: the Italian case study. Expert Opinion on Drug Safety, 2019, 18, 497-509.	2.4	24
41	Antipsychotic utilization patterns among patients with schizophrenic disorder: a cross-national analysis in four countries. European Journal of Clinical Pharmacology, 2019, 75, 1005-1015.	1.9	12
42	Pharmacological therapy in a rare disease: challenges in the long-term management of granulomatosis with polyangiitis. Expert Opinion on Orphan Drugs, 2019, 7, 521-523.	0.8	3
43	Workshop on the Italian Pharmacovigilance System in the International Context: Critical Issues and Perspectives. Drug Safety, 2019, 42, 683-687.	3.2	2
44	Identifying Data Elements to Measure Frailty in a Dutch Nationwide Electronic Medical Record Database for Use in Postmarketing Safety Evaluation: An Exploratory Study. Drug Safety, 2019, 42, 713-719.	3.2	5
45	All-cause mortality and antipsychotic use among elderly persons with high baseline cardiovascular and cerebrovascular risk: a multi-center retrospective cohort study in Italy. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 179-188.	3.3	8
46	The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand?. Drug Safety, 2019, 42, 347-363.	3.2	65
47	Can information on functional and cognitive status improve short-term mortality risk prediction among community-dwelling older people? A cohort study using a UK primary care database. Clinical Epidemiology, 2018, Volume 10, 31-39.	3.0	12
48	Improvement in the management of chronic obstructive pulmonary disease following a clinical educational program: results from a prospective cohort study in the Sicilian general practice setting. Npj Primary Care Respiratory Medicine, 2018, 28, 10.	2.6	9
49	From Big Data to Smart Data for Pharmacovigilance: The Role of Healthcare Databases and Other Emerging Sources. Drug Safety, 2018, 41, 143-149.	3.2	54
50	Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource. Alzheimer's and Dementia, 2018, 14, 130-139.	0.8	44
51	Can Electronic Health Records Databases Complement Spontaneous Reporting System Databases? A Historical-Reconstruction of the Association of Rofecoxib and Acute Myocardial Infarction. Frontiers in Pharmacology, 2018, 9, 594.	3.5	20
52	Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report. Frontiers in Pharmacology, 2018, 9, 608.	3.5	8
53	Pattern of Use of Biosimilar and Originator Somatropin in Italy: A Population-Based Multiple Databases Study During the Years 2009–2014. Frontiers in Endocrinology, 2018, 9, 95.	3.5	17
54	Use of azithromycin and risk of ventricular arrhythmia. Cmaj, 2017, 189, E560-E568.	2.0	42

#	Article	IF	Citations
55	Overview of the Safety of Anti-VEGF Drugs: Analysis of the Italian Spontaneous Reporting System. Drug Safety, 2017, 40, 1131-1140.	3.2	24
56	Antibiotic Use in Children – A Cross-National Analysis of 6 Countries. Journal of Pediatrics, 2017, 182, 239-244.e1.	1.8	90
57	Combining evidence from multiple electronic health care databases: performances of one-stage and two-stage meta-analysis in matched case-control studies. Pharmacoepidemiology and Drug Safety, 2017, 26, 1213-1219.	1.9	7
58	Biological substantiation of antipsychotic-associated pneumonia: Systematic literature review and computational analyses. PLoS ONE, 2017, 12, e0187034.	2.5	20
59	Clinically Relevant Drug Interactions with Anti-Alzheimer's Drugs. CNS and Neurological Disorders - Drug Targets, 2017, 16, 501-513.	1.4	10
60	Prescribing pattern of antipsychotic drugs during the years 1996–2010: a populationâ€based database study in Europe with a focus on torsadogenic drugs. British Journal of Clinical Pharmacology, 2016, 82, 487-497.	2.4	27
61	O2â€05â€02: Dementia Prevalence and Incidence in a Combination of European Electronic Health Records Databases: the EMIFâ€ad EHR Resource. Alzheimer's and Dementia, 2016, 12, P232.	0.8	0
62	Absorbable phosphate in medication. Kidney International, 2016, 89, 721.	<b>5.</b> 2	0
63	Relation of Statin Use and Mortality in Community-Dwelling Frail Older Patients With Coronary Artery Disease. American Journal of Cardiology, 2016, 118, 1624-1630.	1.6	52
64	The Effect of Safety Warnings on Antipsychotic Drug Prescribing in Elderly Persons with Dementia in the United Kingdom and Italy: A Population-Based Study. CNS Drugs, 2016, 30, 1097-1109.	5.9	33
65	Antipsychotic use in dementia patients in a general practice setting: a Dutch population-based study. Epidemiology and Psychiatric Sciences, 2016, 25, 403-406.	3.9	2
66	Effects of a computerized decision support system in improving pharmacological management in high-risk cardiovascular patients: A cluster-randomized open-label controlled trial. Health Informatics Journal, 2016, 22, 232-247.	2.1	10
67	The Management of Diabetes Mellitus in Patients with Chronic Kidney Disease: A Population-Based Study in Southern Italy. Clinical Drug Investigation, 2016, 36, 203-212.	2.2	12
68	Response to comment on: "antibiotic use varies substantially among adults—a cross‑national study from five European Countries in the ARITMO project― Infection, 2016, 44, 135-141.	4.7	1
69	Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study. PLoS ONE, 2016, 11, e0155805.	2.5	27
70	The role of electronic healthcare record databases in paediatric drug safety surveillance: a retrospective cohort study. British Journal of Clinical Pharmacology, 2015, 80, 304-314.	2.4	25
71	Antipsychotic drug exposure and risk of pneumonia: a systematic review and meta-analysis of observational studies. Pharmacoepidemiology and Drug Safety, 2015, 24, 812-820.	1.9	49
72	Association of Individual Non-Steroidal Anti-Inflammatory Drugs and Chronic Kidney Disease: A Population-Based Case Control Study. PLoS ONE, 2015, 10, e0122899.	2.5	62

#	Article	IF	Citations
73	Indications of newer and older antiâ€epileptic drug use: findings from a southern Italian general practice setting from 2005–2011. British Journal of Clinical Pharmacology, 2015, 79, 1010-1019.	2.4	34
74	Erythropoiesis-Stimulating Agents: Dose and Mortality Risk., 2015, 25, 164-168.		14
75	Antipsychotic use in elderly patients and the risk of pneumonia. Expert Opinion on Drug Safety, 2015, 14, 1-6.	2.4	42
76	Drug Interactions with Levothyroxine Therapy in Patients with Hypothyroidism: Observational Study in General Practice. Clinical Drug Investigation, 2015, 35, 187-195.	2.2	28
77	Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety. Expert Opinion on Drug Metabolism and Toxicology, 2015, 11, 883-892.	3.3	59
78	Development and Validation of a Score for Adjusting Health Care Costs in General Practice. Value in Health, 2015, 18, 884-895.	0.3	8
79	Trends in the prescription of antidiabetic medications from 2009 to 2012 in a general practice of Southern Italy: A population-based study. Diabetes Research and Clinical Practice, 2015, 108, 157-163.	2.8	39
80	Evaluating performance of electronic healthcare records and spontaneous reporting data in drug safety signal detection. International Journal of Clinical Pharmacy, 2015, 37, 94-104.	2.1	31
81	Useful Interplay Between Spontaneous ADR Reports and Electronic Healthcare Records in Signal Detection. Drug Safety, 2015, 38, 1201-1210.	3.2	49
82	Medication is an additional source of phosphate intake in chronic kidney disease patients. Nutrition, Metabolism and Cardiovascular Diseases, 2015, 25, 959-967.	2.6	13
83	How healthy is community-dwelling elderly population? Results from Southern Italy. Translational Medicine @ UniSa, 2015, 13, 59-64.	0.5	9
84	The Burden of Nephrotoxic Drug Prescriptions in Patients with Chronic Kidney Disease: A Retrospective Population-Based Study in Southern Italy. PLoS ONE, 2014, 9, e89072.	2.5	50
85	High Prevalence of Poor Quality Drug Prescribing in Older Individuals: A Nationwide Report From the Italian Medicines Agency (AIFA). Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2014, 69, 430-437.	3.6	86
86	Expert opinion of nephrologists about the effectiveness of low-protein diet in different stages of chronic kidney disease (CKD). International Journal of Food Sciences and Nutrition, 2014, 65, 1027-1032.	2.8	2
87	Chronic Kidney Disease Requiring Healthcare Services: A New Approach to Evaluate Epidemiology of Renal Disease. BioMed Research International, 2014, 2014, 1-6.	1.9	14
88	Validation study in four health-care databases: upper gastrointestinal bleeding misclassification affects precision but not magnitude of drug-related upper gastrointestinal bleeding risk. Journal of Clinical Epidemiology, 2014, 67, 921-931.	5.0	49
89	Changes in the prescribing pattern of antidepressant drugs in elderly patients: an Italian, nationwide, population-based study. European Journal of Clinical Pharmacology, 2014, 70, 469-478.	1.9	31
90	Are the Safety Profiles of Antipsychotic Drugs Used in Dementia the Same? An Updated Review of Observational Studies. Drug Safety, 2014, 37, 501-520.	3.2	34

#	Article	IF	CITATIONS
91	Effect of an Educational Program in Primary Care: The Case of Lipid Control in Cardio-Cerebrovascular Prevention. International Journal of Immunopathology and Pharmacology, 2014, 27, 351-363.	2.1	11
92	Pattern of Statin Use in Southern Italian Primary Care: Can Prescription Databases Be Used for Monitoring Long-Term Adherence to the Treatment?. PLoS ONE, 2014, 9, e102146.	2.5	38
93	A nationwide prospective study on prescribing pattern of antidepressant drugs in Italian primary care. European Journal of Clinical Pharmacology, 2013, 69, 227-236.	1.9	28
94	Effects of L'Aquila earthquake on the prescribing pattern of antidepressant and antipsychotic drugs. International Journal of Clinical Pharmacy, 2013, 35, 1053-1062.	2.1	14
95	Harmonization process for the identification of medical events in eight European healthcare databases: the experience from the EU-ADR project. Journal of the American Medical Informatics Association: JAMIA, 2013, 20, 184-192.	4.4	75
96	Epidemiology of gout and hyperuricaemia in Italy during the years 2005–2009: a nationwide population-based study. Annals of the Rheumatic Diseases, 2013, 72, 694-700.	0.9	231
97	Clinical and economic burden of adverse drug reactions. Journal of Pharmacology and Pharmacotherapeutics, 2013, 4, S73-S77.	0.4	329
98	Risk of Cardiac Valve Regurgitation with Dopamine Agonist use in Parkinson $\hat{E}^{1}/4$ s Disease and Hyperprolactinaemia. Drug Safety, 2012, 35, 159-171.	3.2	42
99	Adverse Drug Reaction-Related Hospitalizations in Persons Aged 55 Years and Over. Drugs and Aging, 2012, 29, 225-232.	2.7	51
100	Antipsychotic Drug Use and Community-Acquired Pneumonia. Current Infectious Disease Reports, 2011, 13, 262-268.	3.0	51
101	Combining electronic healthcare databases in Europe to allow for largeâ€scale drug safety monitoring: the EUâ€ADR Project. Pharmacoepidemiology and Drug Safety, 2011, 20, 1-11.	1.9	222
102	EU-ADR healthcare database network vs. spontaneous reporting system database: preliminary comparison of signal detection. Studies in Health Technology and Informatics, 2011, 166, 25-30.	0.3	34
103	Risk of Ischemic Stroke Associated With Antidepressant Drug Use in Elderly Persons. Journal of Clinical Psychopharmacology, 2010, 30, 252-258.	1.4	51
104	Prescribing pattern of antipsychotic drugs in the Italian general population 2000–2005: a focus on elderly with dementia. International Clinical Psychopharmacology, 2010, 25, 22-28.	1.7	27
105	Prescribing pattern of antiâ€epileptic drugs in an Italian setting of elderly outpatients: a populationâ€based study during 2004–07. British Journal of Clinical Pharmacology, 2010, 70, 514-522.	2.4	41
106	Association of Community-Acquired Pneumonia With Antipsychotic Drug Use in Elderly Patients. Annals of Internal Medicine, 2010, 152, 418.	3.9	132
107	Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor?. Pharmacoepidemiology and Drug Safety, 2009, 18, 1176-1184.	1.9	162
108	Newer and older antiepileptic drug use in Southern Italy: A population-based study during the years 2003–2005. Epilepsy Research, 2009, 85, 107-113.	1.6	35

#	Article	IF	CITATION
109	Use of antipsychotics in elderly patients with dementia: Do atypical and conventional agents have a similar safety profile?. Pharmacological Research, 2009, 59, 1-12.	7.1	93
110	The EU-ADR project: preliminary results and perspective. Studies in Health Technology and Informatics, 2009, 148, 43-9.	0.3	37
111	Prescribing pattern of drugs in the treatment of osteoarthritis in italian general practice: The effect of rofecoxib withdrawal. Arthritis and Rheumatism, 2008, 59, 568-574.	6.7	36
112	Prescribing pattern of anti-Parkinson drugs in Southern Italy: Cross-sectional analysis in the years 2003–2005. Parkinsonism and Related Disorders, 2008, 14, 420-425.	2.2	28
113	Risk of stroke with typical and atypical anti-psychotics: a retrospective cohort study including unexposed subjects. Journal of Psychopharmacology, 2008, 22, 39-46.	4.0	89
114	Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003–2004. Pharmacoepidemiology and Drug Safety, 2007, 16, 552-559.	1.9	59
115	All-cause mortality associated with atypical and typical antipsychotics in demented outpatients. Pharmacoepidemiology and Drug Safety, 2007, 16, 538-544.	1.9	71
116	Interaction risk with proton pump inhibitors in general practice: significant disagreement between different drug-related information sources. British Journal of Clinical Pharmacology, 2006, 62, 582-590.	2.4	47
117	Antipsychotic prescribing pattern among Italian general practitioners: a population-based study during the years 1999?2002. European Journal of Clinical Pharmacology, 2005, 61, 47-53.	1.9	54
118	Statin–macrolide interaction risk: a population-based study throughout a general practice database. European Journal of Clinical Pharmacology, 2005, 61, 615-620.	1.9	32
119	Adverse drug events in emergency department population: a prospective Italian study. Pharmacoepidemiology and Drug Safety, 2005, 14, 333-340.	1.9	57